Pfizer Chooses UnitedLex to Manage Document Review Services

Updated

Pfizer Chooses UnitedLex to Manage Document Review Services

UnitedLex Recognized as the Leader in Global Document Review

OVERLAND PARK, Kan.--(BUSINESS WIRE)-- UnitedLex, a global provider of legal and business technology consulting services, announces it has been selected to be the primary managed document review provider to Pfizer Inc. [NYSE: PFE], the world's largest research-based pharmaceutical company.


UnitedLex will ensure global delivery of Pfizer's extensive managed document review process by supporting real-time communications with internal and external counsel through the most advanced video conferencing capabilities, rigorous quality control processes, daily metrics reporting, proprietary multi-shore workflow and defined project intake and delivery methods. UnitedLex manages document review for Fortune 500 companies and AmLaw 100 law firms from facilities in the United States, India, the United Kingdom and Israel.

"Pfizer has been an innovator in restructuring the litigation management process and being selected to control one of its most critical functions is an honor," said Dave Deppe, President of UnitedLex. "With more than 750 professionals in nine global offices and two data centers, UnitedLex is ideally suited to partner with a company of Pfizer's caliber and sophistication."

"Pfizer's discovery model calls for a collaborative partner with extensive global delivery capability that embraces the operational efficiencies and advanced technologies required in today's discovery environment, while also remaining cognizant of the cost pressures large corporations face," said Ed Gramling, Pfizer's Discovery Counsel. "UnitedLex has proven they can deliver a superior work product in conjunction with highly competitive pricing and we are excited to have them on board."

"Each year UnitedLex handles large, complex, 'bet-the-company' litigation matters for the world's best-run companies. We look forward to the opportunity to apply our expertise to Pfizer's most important litigation matters," said Ryan Reeves, Senior Vice President of U.S. Operations for UnitedLex.

UnitedLex was awarded the position of Pfizer's primary global document review provider after several pilot projects, intense calibration and scalability exercises, rigorous quality validations and many in depth operational and security audits. Toward the end of the diligence period, members of Pfizer's legal team traveled to the UnitedLex Gurgaon, India facility in January of 2013. UnitedLex executives were joined by Pfizer's Ed Gramling, Discovery Counsel, Grace Park, Senior Corporate Counsel and Anthony Mosquera, Senior Legal Discovery Manager to perform an in depth analysis of UnitedLex's global operations. Ryan Reeves will lead the initiative on behalf of UnitedLex to ensure continued improvements across the established Pfizer Discovery platform with ultimate focus on quality of work product delivered from the UnitedLex global delivery platform.

About UnitedLex

UnitedLex (www.unitedlex.com) is a global company with a singular mission to improve the performance of law departments and law firms. We provide unparalleled solutions to address the risk, efficiency and effectiveness goals of our clients in North America, Europe and Asia. Our more than 750 attorneys, engineers and consultants focus on the broadly defined areas of litigation, contracting, intellectual property and operations to drive seven and eight figure benefit to our clients. Founded in 2006 and with more than $250 million in assets, UnitedLex deploys the right blend of service and technology in supporting the world's leading corporations and law firms.



UnitedLex
Kristie Kushner, 1-678-575-7558
kristie.kushner@unitedlex.com
or
Infinite PR
Jamie Diaferia, 212-687-0935
jdiaferia@infinitepr.com

KEYWORDS: United States North America Kansas

INDUSTRY KEYWORDS:

The article Pfizer Chooses UnitedLex to Manage Document Review Services originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement